Disease‑Modifying Therapy for Ocular Surface Disease

While 17.8 million people have been diagnosed with Dry Eye Disease in the United States…

Fewer than 1 million (1 in 20) are currently treated with an FDA-approved product; presumably due to questionable efficacy and tolerability limitations.

Less than 5% (1 in 20) of Dry Eye Disease patients are currently treated with a FDA-approved product

Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease

Learn more about Aramis Biosciences

News

Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

November 3, 2022

Aramis Biosciences Announces First Patient Dosed in Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

February 28, 2022

See all

Events

There are no upcoming events.

See all

Get in touch

Please provide a brief description of your inquiry and we’ll get back to you as soon as we can.

Message